Drug intelligence / Profile preview

apricoxib

Development stage: Phase 2
Lead developer: Cothera Bioscience
Modality: Small Molecules

Overview

Apricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor. It was developed for its anti-inflammatory and antineoplastic properties, particularly in treating cancers such as non-small cell lung cancer and pancreatic cancer. Apricoxib has shown potential in reversing epithelial-to-mesenchymal transition (EMT), a process involved in cancer progression and metastasis.

Brand names: Capoxigem
Other names: apricoxib

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on apricoxib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on apricoxib.

Explore the full profile